Bayer donates medicines worth R1.3 million to Charlotte Maxeke Hospital

  • Emergency medicinal aid to help enable public health authorities as they fight coronavirus by helping the elderly
Charlotte Maxeke receiving Bayer medicine

Johannesburg, April 9, 2020- Bayer has stepped in to help the Charlotte Maxeke Hospital in Johannesburg, Gauteng with a donation of R1,3 million worth of medicines. The medicine is one of Bayer’s most innovative and will assist the hospital in treating impoverished, elderly citizens by helping them to reduce these vulnerable patients visits to the hospital at this critical time in the fight against the coronavirus. Charlotte Maxeke Hospital is a government-designated coronavirus testing and treatment hospital in Johannesburg.


Country Divisional Head for Bayer’s Pharmaceutical Division in Southern Africa, Frans Labuschagne explains that this donation will help the health authorities to lessen the chances of these vulnerable patients being infected by the coronavirus, “Considering that Gauteng is dealing with the country’s highest number of coronavirus cases, it is imperative that our public health resources can remain focused on treating and containing the coronavirus. By providing this medicine to Charlotte Maxeke Hospital, we are hoping to help the hospital treat at least 700 older patients who would otherwise have to visit the hospital several times to help manage their condition, but will now be placed on Bayer’s self-regulating treatment, that will free-up much needed public health resources and reduce the risk of exposure to the coronavirus in a crowded hospital environment.”


Apart from this donation, Bayer has committed considerable financial and material support to various countries including China, Italy, Germany and the United States to help contain the pandemic. Bayer will continue to provide affected regions and countries with rapid and unbureaucratic assistance as part of its corporate social responsibility.


About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to .




Tasniem Patel

Mobile +27 82 8732423

Head of Communications for Southern Africa



Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.